Although drug testing occurs in nearly every addiction treatment setting, there is a lack of evidence-based guidance regarding test frequency, test interpretation, and which drugs to test for. Drug testing practices vary widely.
Drug testing has been referred to as “the technology of addiction treatment,” but like any technology, its value depends on whether it is utilized correctly. Inappropriate testing practices can alienate or traumatize patients, produce inaccurate results, and pose risks to patient safety.
The inappropriate use of drug testing not only compromises clinical care, but it opens the door to fraud, which can have extraordinary costs to third party payers, taxpayers, and at times the patients who are receiving care.
In collaboration with the American Society for Addiction Medicine, IRETA built an Appropriateness Document describing drug testing practices that are supported by empirical evidence and clinical expertise. One of the purposes of this document was to clarify appropriate clinical use of drug testing and, in so doing, shine a light on drug testing practices that are clearly outside of these boundaries.
To determine appropriate clinical practice, IRETA utilized the RAND/UCLA Appropriateness Method, which has a higher level of methodological rigor than consensus methods.
IRETA also provided technical assistance for disseminating the document and creating supplemental educational tools.
The document was approved by ASAM’s Board of Directors in 2017.